Patents by Inventor Linda R. Gritz

Linda R. Gritz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • System for treating and preventing breast cancer
    Patent number: 8933041
    Abstract: The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: January 13, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Jeffrey Schlom, Kwong-Yok Tsang, James W. Hodge
  • Custom vectors for treating and preventing pancreatic cancer
    Patent number: 8901093
    Abstract: The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: December 2, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Jeffrey Schlom, Kwong-Yok Tsang, James W. Hodge
  • Modified CEA nucleic acid and expression vectors
    Patent number: 8530442
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: September 10, 2013
    Assignee: Sanofi Pasteur Limited
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS
    Publication number: 20130101625
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Application
    Filed: June 25, 2012
    Publication date: April 25, 2013
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • Modified CEA nucleic acid and expression vectors
    Patent number: 8236776
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: August 7, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS
    Publication number: 20100285065
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Application
    Filed: March 2, 2010
    Publication date: November 11, 2010
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • Modified CEA nucleic acid and expression vectors
    Patent number: 7786278
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: August 31, 2010
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • NOVEL INSERTION SITES IN POX VECTORS
    Publication number: 20100136056
    Abstract: The present invention provides novel insertion sites for introducing DNA into pox vectors.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 3, 2010
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Patricia Greenhalgh
  • Insertion sites in fowlpox vectors
    Patent number: 7638134
    Abstract: The present invention provides novel insertion sites for introducing DNA into pox vectors.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: December 29, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Patricia Greenhalgh
  • Recombinant pox virus for immunization against tumor-associated antigens
    Patent number: 7410644
    Abstract: Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: August 12, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey Schlom, Dennis L. Panicali, Linda R. Gritz, Gail P. Mazzara
  • Custom Vectors for Treating and Preventing Pancreatic Cancer
    Publication number: 20080166367
    Abstract: The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
    Type: Application
    Filed: November 12, 2004
    Publication date: July 10, 2008
    Inventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Jeffrey Schlom, Kwong-Yok Tsang, James W. Hodge
  • Recombinant pox virus for immunization against tumor-associated antigens
    Publication number: 20030003079
    Abstract: Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
    Type: Application
    Filed: July 17, 2002
    Publication date: January 2, 2003
    Inventors: Jeffrey Schlom, Dennis L. Panicali, Linda R. Gritz, Gail P. Mazzara
  • Self-assembled, defective, nonself-propagating viral particles
    Patent number: 6051410
    Abstract: Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: April 18, 2000
    Assignee: Therion Biologics, Corp.
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard, Anna Mahr
  • Self assembled, defective, nonself-propagating viral particles
    Patent number: 5804196
    Abstract: Recombinant avipox viral vectors which express heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The recombinant avipox viruses can be used to produce significant amounts of the heterologous polypeptides in avian or non-avian cells. Preferably, the recombinant avipox virus is a fowlpox virus. The viral particles can also be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 8, 1998
    Assignee: Therion Biologics Corporation
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard
  • Self-assembled, defective, non-self-propagating lentivirus particles
    Patent number: 5747324
    Abstract: The present invention provides recombinant DNA viral vectors which co-express lentivirus genes encoding structural and enzymatic polypeptides capable of assembling into defective nonself-propagating viral particles. The viral DNA vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and genes.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: May 5, 1998
    Assignee: Therion Biologics Corporation
    Inventors: Gail P. Mazzara, Bryan Roberts, Dennis L. Panicali, Linda R. Gritz, Virginia Stallard, Anna Mahr
  • Self assembled defective non-self propagating lentiviral particles
    Patent number: 5736368
    Abstract: Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective non-self-propagating lentiviral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 7, 1998
    Assignee: Therion Biologics Corporation
    Inventors: Gail P. Mazzara, Bryan Roberts, Dennis L. Panicali, Virginia Stallard, Linda R. Gritz
  • Generation of hybrid genes and proteins by virus-mediated recombination
    Patent number: 5691170
    Abstract: The ability of viruses to undergo recombination within tandemly arranged homologous sequences can be utilized to generate chimeric genes and proteins. Tandemly arranged homologous sequences will rapidly degenerate in a random fashion to yield a single copy comprised of portions of both original sequences. Therefore, a recombinant virus which contains two related but non-identical genes in tandem array yields a population of recombinant viruses which contain a spectrum of hybrid sequences derived from recombination between the original genes. The viruses, therefore, contain hybrid DNA sequences that encode proteins with new epitopes or different combinations of epitopes. Vaccines are derived which may afford protection against a broad spectrum of antigen types.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: November 25, 1997
    Assignee: Therion Biologics
    Inventors: Linda R. Gritz, Dennis L. Panicali
  • Methods of in vivo gene delivery
    Patent number: 5656465
    Abstract: We have discovered that using non-integrative viral vectors having low replicative efficiency for insertion of a gene into a cell such as a lymphocyte or a tumor cell is a preferred system for transforming such cells for use in somatic cell therapy or gene therapy. These vectors are preferably cytoplasmic viral vectors, as opposed to nuclear viral vectors. Preferred cytoplasmic vectors include DNA viruses such as pox viruses and iridoviruses and RNA viruses such as picornavirus, calicivirus and togavirus. More preferably the virus used will not be capable of sustained replication in the target cell. For example, a preferred pox virus for human cells will be an avipox, or suipox in contrast to an orthopox virus such as vaccinia.
    Type: Grant
    Filed: May 4, 1994
    Date of Patent: August 12, 1997
    Assignee: Therion Biologics Corporation
    Inventors: Dennis L. Panicali, Steven A. Rosenberg, Linda R. Gritz
  • Self assembled, defective, non-self-propagating lentivirus particles
    Patent number: 5631154
    Abstract: Recombinant avipox viral vectors which express heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The recombinant avipox viruses can be used to produce significant amounts of the heterologous polypeptides in avian or non-avian cells. Preferably, the recombinant avipox virus is a fowlpox virus. The viral particles can also be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: May 20, 1997
    Assignee: Therion Biologics, Incorporated
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard, Anna Mahr
  • Self-assembled, defective, non-self-propagating lentivirus particles
    Patent number: 5614404
    Abstract: Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: March 25, 1997
    Assignee: Theriod Biologics, Incorporated
    Inventors: Gail P. Mazzara, Bryan Roberts, Dennis L. Panicali, Virginia Stallard, Linda R. Gritz, Anna Mahe